Blog
RSS FeedPosted by Michael Wonder on 24 Aug 2020
FDA's convalescent plasma EUA requires all donor blood units be tested only with Ortho's COVID-19 IgG antibody test
24 August 2020 - In its August 23 Emergency Use Authorisation for COVID-19 convalescent plasma for the treatment of hospitalised ...
Posted by Michael Wonder on 23 Aug 2020
FDA issues emergency use authorisation for convalescent plasma as potential promising COVID–19 treatment, another achievement in Administration’s fight against pandemic
23 August 2020 - Today, the U.S. FDA issued an emergency use authorisation for investigational convalescent plasma for the treatment ...
Posted by Michael Wonder on 30 Jul 2020
FDA nears decision authorising COVID-19 treatment with convalescent plasma
29 July 2020 - Antibody-rich blood plasma would be one of the first coronavirus treatments to receive approval, which could pave ...
Posted by Michael Wonder on 07 May 2020
CSL Behring Australia commences development of treatment for serious cases of COVID-19
6 May 2020 - Plasma-derived therapeutic with potential to treat serious complications of COVID-19. ...
Posted by Michael Wonder on 06 May 2020
COVID-19: potentially life saving immunoglobulin treatment for seriously ill Australians
6 May 2020 - The Australian Government welcomes the announcement by CSL Behring that Australia will be one of the first ...
Posted by Michael Wonder on 06 May 2020
CSL ramps up development of COVID-19 plasma treatment
6 May 2020 - Australia’s biggest health company CSL has confirmed it will immediately begin development of plasma-derived therapy to ...
Posted by Michael Wonder on 03 May 2020
Pharming receives European Commission approval for treatment of acute hereditary angioedema attacks in children with Ruconest
30 April 2020 - European Commission decision was received six weeks earlier than expected. ...
Posted by Michael Wonder on 25 Apr 2020
CSL's blood payments in US under the microscope
25 April 2020 - CSL has been forced to defend the way it runs its blood plasma collection business in ...
Posted by Michael Wonder on 08 Apr 2020
Cows come home for CSL in COVID-19 vaccine battle
8 April 2020 - It sounds like a pitch for a sci-fi thriller — using genetically modified cows to fight ...
Posted by Michael Wonder on 07 Apr 2020
Global plasma leaders collaborate to accelerate development of potential COVID-19 hyperimmune therapy
6 April 2020 - Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the ...
Posted by Michael Wonder on 01 Apr 2020
FDA approves additional treatment for adults and adolescents with haemophilia A or B and inhibitors
1 April 2020 - The U.S. FDA today approved Sevenfact [coagulation factor VIIa (recombinant)-jncw] for the treatment and control of bleeding ...
Posted by Michael Wonder on 06 Nov 2019
Octapharma’s fibryga receives European label extension to treat acquired fibrinogen deficiency (AFD)
5 November 2019 - Octapharma announced today that the human fibrinogen concentrate fibryga has received approval for use in treatment of ...
Posted by Michael Wonder on 05 Nov 2019
A severe shortage hits a drug used for cancer, immune disorders, epilepsy, causing canceled treatments and rationing
5 November 2019 - A severe shortage of immune globulin — a popular medicine used to treat epilepsy, cancer and ...
Posted by Michael Wonder on 08 Oct 2019
FDA approves Octapharma’s Wilate for haemophilia A in adult and adolescent patients
8 October 2019 - Octapharma USA today announced the U.S. FDA has approved Wilate for treatment of adults and adolescents with ...
Posted by Michael Wonder on 29 Jul 2019
Platelet rich plasma treatment is not classified as a drug, Health Canada says
27 July 2019 - Agency clarifies its position on controversial treatment made popular by superstar athletes. ...